SCHEMBL4023712

SCHEMBL4023712

COC(=O)c1cc(N=C=O)cc(C(=O)OC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.51
POLB P06746 2/20 0.51
CA12 O43570 3/20 0.48
CA1 P00915 3/20 0.48
CA2 P00918 3/20 0.48
CA7 P43166 3/20 0.48
CA9 Q16790 3/20 0.48
CA14 Q9ULX7 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
LMNA P02545 2/20 0.47
XDH P47989 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
GAA P10253 1/20 0.47
NFKB1 P19838 1/20 0.47
GFER P55789 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
FUT7 Q11130 1/20 0.47
ALDH1A1 P00352 4/20 0.44
MAPT P10636 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18874914 0.93 KDM4E (0.46) KDM4EPOLBCA12CA1CA2
SCHEMBL14293379 0.90 KDM4E (0.44) KDM4EPOLBCA12CA1CA2
SCHEMBL31609061 0.84 NOTUM (0.57) KDM4EPOLBCA12CA1CA2
SCHEMBL40349 0.82 CYP4F2 (0.51) POLBCA12CA1CA2CA7
SCHEMBL445414 0.81 RAB9A (0.58) CA12CA1CA2CA7CA9
SCHEMBL8107775 0.81 TRPA1 (0.49) KDM4EPOLBL3MBTL1LMNAALDH1A1
SCHEMBL147169 0.78 CA1 (0.71) KDM4EPOLBCA12CA1CA2
SCHEMBL7232358 0.78 CYP3A4 (0.47) KDM4EPOLBCA12CA1CA2
SCHEMBL19351446 0.78 TSHR (0.62) POLBCA12CA1CA2CA7
SCHEMBL8244636 0.78 KDM4E (0.56) KDM4EPOLBCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713378-A1 ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS Covestro Deutschland AG (DE) 2026-03-25 EP disclosed
EP-3774961-B1 ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS COVESTRO DEUTSCHLAND AG (DE) 2025-01-15 EP disclosed
WO-2024236000-A1 ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS COVESTRO DEUTSCHLAND AG (DE) 2024-11-21 WO disclosed
EP-4464727-A1 ESTERIFIED ETHANOLAMINES FOR THE PREPARATION OF ISOCYANURATE POLYMERS Covestro Deutschland AG (DE) 2024-11-20 EP disclosed
US-20240150515-A1 Low Viscosity Catalyst Compositions for Producing Isocyanurate Polymers COVESTRO DEUTSCHLAND AG (DE) 2024-05-09 US disclosed
CN-117402418-B High-wear-resistance rubber hose and preparation method thereof 河北润驰流体科技有限公司 2024-02-27 CN disclosed
CN-117402418-A High-wear-resistance rubber hose and preparation method thereof 河北润驰流体科技有限公司 2024-01-16 CN disclosed
EP-4298140-A1 LOW VISCOSITY CATALYST COMPOSITIONS FOR PRODUCING ISOCYANURATE POLYMERS Covestro Deutschland AG (DE) 2024-01-03 EP disclosed
CN-116917364-A Low viscosity catalyst composition for producing isocyanurate polymers 科思创德国股份有限公司 2023-10-20 CN disclosed
CN-112020525-B Adducts of amine catalysts for preparing isocyanurate polymers 科思创知识产权两合公司 2023-05-16 CN disclosed
US-20070014751-A1 Novel spiro-quinuclidinyl derivatives for the treatment of central nervous system disorders JANSSEN PHARMACEUTICAL, N.V. (BE) 2007-01-18 US disclosed
US-20070004715-A1 Novel spiro-quinuclidinyl derivatives for the treatment of central nervous system disorders JANSSEN PHARMACEUTICAL, N.V., A CORP. OF BELGIUM (BE) 2007-01-04 US disclosed
US-6653295-B2 Protease inhibitor; viricide BRISTOL-MYERS SQUIBB COMPANY 2003-11-25 US disclosed
US-20030064962-A1 Inhibitors of hepatitis C virus NS3 protease BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) 2003-04-03 US disclosed
WO-2002048116-A2 INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2002-06-20 WO disclosed
US-5942387-A Combinatorial process for preparing substituted thiophene libraries ELI LILLY AND COMPANY (US) 1999-08-24 US disclosed
EP-0880558-A1 COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED INDANE LIBRARIES ELI LILLY AND COMPANY (US) 1998-12-02 EP disclosed
WO-1998008839-A1 COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED THIOPHENE LIBRARIES ELI LILLY AND COMPANY (US) 1998-03-05 WO disclosed
EP-0816309-A1 Scavenger assisted combinatorial process for preparing libraries of urea and thiourea compounds ELI LILLY AND COMPANY (US) 1998-01-07 EP disclosed
WO-1997026300-A1 COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED INDANE LIBRARIES ELI LILLY AND COMPANY (US) 1997-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064962-A1 Inhibitors of hepatitis C virus NS3 protease PRSS1, SERPINB1, SPINT2 KDM4E 2515/4885POLB 3575/4885CA12 4025/4885
US-20070014751-A1 Novel spiro-quinuclidinyl derivatives for the treatment of central nervous system disorders GRIN2C, GRIN2A, CHRNA2 KDM4E 4124/4885POLB 4504/4885CA12 3026/4885
US-20070004715-A1 Novel spiro-quinuclidinyl derivatives for the treatment of central nervous system disorders GRIN2C, GRIN2A, CHRNA2 KDM4E 4124/4885POLB 4504/4885CA12 3026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.